Literature DB >> 16557201

Cancer screening with FDG-PET.

M Ide1.   

Abstract

AIM: Thi study is based on medical health check-up and cancer screening on of a medical health club using PET, MRI, spiral CT and other conventional examinations.
METHODS: Between October 1994 and June 2005, 9,357 asymptomatic members of the health club participated in 24,772 screening session (5,693 men and 3,664 women, mean age was 52.2+/-10.4 years).
RESULTS: Malignant tumors were discovered in 296 of the 9,357 participants (3.16%) and 24,772 screening sessions (1.19%). The detection rate of our program is much higher than that of mass screening in Japan. The thyroid, lung, colon and breast cancers were PET positive, but the prostate, renal and bladder cancers were generally PET negative.
CONCLUSIONS: FDG-PET has the potential to detect a wide variety of cancers at curable stages in asymptomatic individuals. To reduce false-positive and false-negative results of PET examination, there is a need for experienced radiologist and/or oncologists who had training in the wide aspect of FDG-PET. FDG-PET has limitations in the detection of urological cancers, cancers of low cell density, small cancers and hypometabolic or FDG non-avid cancers. Therefore, conventional examinations and/or PET/CT are also needed for cancer screening in association with FDG-PET.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16557201

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  14 in total

1.  Incidental fleurodeoxyglucose uptake in the prostate.

Authors:  W L Wong; R N Moule; T Nunan
Journal:  Br J Radiol       Date:  2010-11       Impact factor: 3.039

2.  Detection of relevant colonic neoplasms with PET/CT: promising accuracy with minimal CT dose and a standardised PET cut-off.

Authors:  Wolfgang Luboldt; Teresa Volker; Bärbel Wiedemann; Klaus Zöphel; Ursula Wehrmann; Arne Koch; Todd Toussaint; Nasreddin Abolmaali; Markus Middendorp; Daniela Aust; Jörg Kotzerke; Frank Grünwald; Thomas J Vogl; Hans-Joachim Luboldt
Journal:  Eur Radiol       Date:  2010-05-26       Impact factor: 5.315

3.  Targeting breast cancer with sugar-coated carbon nanotubes.

Authors:  Cale D Fahrenholtz; Mallinath Hadimani; S Bruce King; Suzy V Torti; Ravi Singh
Journal:  Nanomedicine (Lond)       Date:  2015-08-21       Impact factor: 5.307

4.  A case of early stage lung cancer detected by repeated cancer screening with positron emission tomography.

Authors:  Ikuko Sakata; Yuichi Ozeki; Katsumi Tamura; Jiro Ishida; Shinsuke Aida; Yoshiyuki Abe
Journal:  Oncol Lett       Date:  2011-11-22       Impact factor: 2.967

5.  Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAFV600E In Vivo.

Authors:  Michael L Schulte; Matthew R Hight; Gregory D Ayers; Qi Liu; Yu Shyr; M Kay Washington; H Charles Manning
Journal:  Mol Imaging Biol       Date:  2017-06       Impact factor: 3.488

6.  Diagnostic accuracy of FDG-PET cancer screening in asymptomatic individuals: use of record linkage from the Osaka Cancer Registry.

Authors:  Tami Sengoku; Kaname Matsumura; Masahisa Usami; Yoshimitsu Takahashi; Takeo Nakayama
Journal:  Int J Clin Oncol       Date:  2014-02-01       Impact factor: 3.402

7.  Pharmacokinetics, metabolism, biodistribution, radiation dosimetry, and toxicology of (18)F-fluoroacetate ((18)F-FACE) in non-human primates.

Authors:  Ryuichi Nishii; William Tong; Richard Wendt; Suren Soghomonyan; Uday Mukhopadhyay; Julius Balatoni; Osama Mawlawi; Luc Bidaut; Peggy Tinkey; Agatha Borne; Mian Alauddin; Carlos Gonzalez-Lepera; Bijun Yang; Juri G Gelovani
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

8.  Automated radiosynthesis of 5-[11C]l-glutamine, an important tracer for glutamine utilization.

Authors:  Adam J Rosenberg; Michael L Nickels; Michael L Schulte; H Charles Manning
Journal:  Nucl Med Biol       Date:  2018-10-15       Impact factor: 2.408

9.  Comparison of FDG-PET/CT for Cancer Detection in Populations With Different Risks of Underlying Malignancy.

Authors:  Hung-Pin Chan; Wen-Shan Liu; Wen-Shiung Liou; Chin Hu; Yu-Li Chiu; Nan-Jing Peng
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

Review 10.  [(18)F]Fluorodeoxyglucose-positron emission tomography screening for lung cancer: a systematic review and meta-analysis.

Authors:  Chun-Ru Chien; Ji-An Liang; Jin-Hua Chen; Hsiao-Nin Wang; Cheng-Chieh Lin; Chih-Yi Chen; Pin-Hui Wang; Chia-Hung Kao; Jun-Jun Yeh
Journal:  Cancer Imaging       Date:  2013-12-14       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.